-DOCSTART- -X- O
In -X- _ O
pediatric -X- _ B-Patient
patients -X- _ I-Patient
with -X- _ I-Patient
malignancy -X- _ I-Patient
and -X- _ I-Patient
those -X- _ I-Patient
receiving -X- _ I-Patient
hematopoietic -X- _ I-Patient
stem -X- _ I-Patient
cell -X- _ I-Patient
transplants -X- _ I-Patient
, -X- _ O
bacterial -X- _ O
and -X- _ O
fungal -X- _ O
infections -X- _ O
have -X- _ O
been -X- _ O
the -X- _ O
focus -X- _ O
of -X- _ O
fever -X- _ O
and -X- _ O
neutropenia -X- _ O
episodes -X- _ O
for -X- _ O
decades. -X- _ O
However -X- _ O
, -X- _ O
improved -X- _ O
diagnostic -X- _ O
capabilities -X- _ O
have -X- _ O
revealed -X- _ O
viral -X- _ O
pathogens -X- _ O
as -X- _ O
a -X- _ O
significant -X- _ O
cause -X- _ O
of -X- _ O
morbidity -X- _ O
and -X- _ O
mortality. -X- _ O
Because -X- _ O
of -X- _ O
limited -X- _ O
effective -X- _ O
antiviral -X- _ O
therapies -X- _ O
, -X- _ O
prevention -X- _ O
of -X- _ O
viral -X- _ O
infections -X- _ O
is -X- _ O
paramount. -X- _ O
Pre-exposure -X- _ B-Intervention
and -X- _ I-Intervention
post-exposure -X- _ I-Intervention
prophylaxis -X- _ I-Intervention
and -X- _ I-Intervention
antiviral -X- _ I-Intervention
suppressive -X- _ O
therapeutic -X- _ O
approaches -X- _ O
are -X- _ O
reviewed. -X- _ O
Additionally -X- _ O
, -X- _ O
infection -X- _ B-Intervention
control -X- _ I-Intervention
practices -X- _ I-Intervention
specific -X- _ O
to -X- _ O
this -X- _ O
patient -X- _ O
population -X- _ O
are -X- _ O
discussed. -X- _ O
A -X- _ O
comprehensive -X- _ O
approach -X- _ O
utilizing -X- _ O
each -X- _ O
of -X- _ O
these -X- _ O
can -X- _ O
be -X- _ O
effective -X- _ O
at -X- _ O
reducing -X- _ O
the -X- _ O
negative -X- _ O
impact -X- _ O
of -X- _ O
viral -X- _ O
infections -X- _ O
. -X- _ O

